Evidence map›Paper›PMID 26383769›Full record

ReviewHuman vaccines & immunotherapeutics2016

Polio elimination in Nigeria: A review.

Usman Nakakana Nasir, Ananda Sankar Bandyopadhyay, Francesca Montagnani, Jacqueline Elaine Akite, Etaluka Blanche Mungu, Ifeanyi Valentine Uche, Ahmed Mohammed Ismaila

Abstract readReview
In one paragraph

Review in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Eradication of wild poliovirus in Nigeria: Lessons learnt.Public health in practice (Oxford, England) · 2021
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Usman Nakakana Nasira Department of Pediatrics , Usmanu Danfodio University Teaching Hospital , Sokoto , Nigeria.
Ananda Sankar Bandyopadhyayc Bill and Melinda Gates Foundation , Seattle , WA , USA.
Francesca Montagnanid Dipartimento di Biotecnologie Mediche , Università di Siena Malattie Infettive Universitarie , Policlinico Le Scotte , Siena, Italy.
Jacqueline Elaine Akiteb Novartis Vaccines Academy , Siena , Italy.
Etaluka Blanche Mungub Novartis Vaccines Academy , Siena , Italy.
Ifeanyi Valentine Ucheb Novartis Vaccines Academy , Siena , Italy.
Ahmed Mohammed Ismailaf Department of Community Medicine , Usmanu Danfodio University Teaching Hospital , Sokoto , Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nigeria has made tremendous strides towards eliminating polio and has been free of wild polio virus (WPV) for more than a year as of August 2015. However, sustained focus towards getting rid of all types of poliovirus by improving population immunity and enhancing disease surveillance will be needed to ensure it sustains the polio-free status. We reviewed the pertinent literature including published and unpublished, official reports and working documents of the Global Polio Eradication Initiative (GPEI) partners as well as other concerned organizations. The literature were selected based on the following criteria: published in English Language, published after year 2000, relevant content and conformance to the theme of the review and these were sorted accordingly. The challenges facing the Polio Eradication Initiative (PEI) in Nigeria were found to fall into 3 broad categories viz failure to vaccinate, failure of the Oral Polio Vaccine (OPV) and epidemiology of the virus. Failure to vaccinate resulted from insecurity, heterogeneous political support, programmatic limitation in implementation of vaccination campaigns, poor performance of vaccination teams in persistently poor performing Local Government areas and sporadic vaccine refusals in Northern Nigeria. Sub optimal effectiveness of OPV in some settings as well as the rare occurrence of VDPVs associated with OPV type 2 in areas of low immunization coverage were also found to be key issues. Some of the innovations which helped to manage the threats to the PEI include a strong government accountability frame work, change from type 2 containing OPV to bi valent OPVs for supplementary immunization activities (SIA), enhancing environmental surveillance in key states (Sokoto, Kano and Borno) along with an overall improvement in SIA quality. There has been an improvement in coverage of routine immunization and vaccination campaigns, which has resulted in Nigeria being removed from the list of endemic countries following an absence of new cases for an entire year as of September 2015. However, the last mile remains to be crossed and there is need to further improve and sustain the momentum to complete the journey toward polio elimination.

Indexed as

Disease EradicationHumansNigeriaPoliomyelitisPoliovirus VaccinesPoliovirus VaccinesEndemic polioNigeriaPolio eradicationsupplementary immunisation activitiesvaccine refusal

Identifiers

PMID26383769
PMCPMC4964709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.